TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain MetastasesRachel A. Freedman, Nancy U. Lin, Kelly M. Silvestri et al.|Journal of Clinical Oncology|2019Cited by 341
TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).Rachel A. Freedman, Nancy U. Lin, Rebecca Gelman et al.|Journal of Clinical Oncology|2017Cited by 36
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022Rachel A. Freedman, Nancy U. Lin, Rebecca Gelman et al.|Clinical Breast Cancer|2019Cited by 28